Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called itraconazole.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostat
Timeframe: Predose, and at designated timepoints up to 144 hours post-dose
Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of opevesostat
Timeframe: Predose, and at designated timepoints up to 144 hours post-dose
Maximum concentration (Cmax) of opevesostat
Timeframe: Predose, and at designated timepoints up to 144 hours post-dose
Time to Maximum concentration (Tmax) of opevesostat
Timeframe: Predose, and at designated timepoints up to 144 hours post-dose
Apparent terminal half-life (t1/2) of opevesostat
Timeframe: Predose, and at designated timepoints up to 144 hours post-dose
Apparent Clearance (CL/F) of opevesostat
Timeframe: Predose, and at designated timepoints up to 144 hours post-dose
Apparent volume of distribution during terminal phase (Vz/F) of opevesostat
Timeframe: Predose, and at designated timepoints up to 144 hours post-dose